Praxis Precision Medicines $PRAX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| 30mg PRAX-628 NCT06908356 |
P2 | Recruiting | Focal Onset Seizure; Primary Generalized Epilepsy | 50 | 2025-07 |
| 60 mg ulixacaltamide NCT06087276 |
P3 | Recruiting | Essential Tremor | 1000 | 2025-10-10 |
| EMBOLD NCT05818553 |
P2/3 | Active, not recruiting | SCN2A Encephalopathy; SCN8A Encephalopathy | 77 | 2025-11-12 (+26 mo) |
| PRAX-222 - Initial Dose NCT05737784 |
P1/2 | Active, not recruiting | SCN2A-DEE; Epilepsy | 60 | 2026-04-01 (+9 mo) |
| 1mg elsunersen NCT07019922 |
P3 | Recruiting | Epileptic Encephalopathy; SCN2A Encephalopathy | 40 | 2026-12 (+6 mo) |
| EMERALD NCT07010471 |
P3 | Active, not recruiting | Developmental and Epileptic Encephalopathy 1 | 160 | 2026-12 (+8 mo) |
| POWER2 NCT07505004 |
P3 | Active, not recruiting | Focal Epilepsy | 300 | 2027-01 |
| vormatrogine NCT07287163 |
P3 | Enrolling by invitation | Epilepsy, Tonic-Clonic; Focal Seizure | 700 | 2028-05-31 |